Cello Health plc

Equities

CLL

GB00B0310763

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-0.31%	+19.70%

2020	Value Demonstration UK Holdings Limited completed the acquisition of Cello Health plc.	CI
2020	Value Demonstration UK Holdings Limited reached an agreement to acquire Cello Health plc for approximately £170 million.	CI

Cello Group Plc Appoints Stephen Highley as Group Corporate Development Director

May 14, 2013 at 11:30 am IST

Cello Group Plc announced the appointment of Stephen Highley to the Board as Group Corporate Development Director. Stephen Highley is a co-founder of MSI. As Group Corporate Development Director, Stephen will share responsibility for helping drive this process from a Board level.

Latest news about Cello Health plc

Value Demonstration UK Holdings Limited completed the acquisition of Cello Health plc.	11/20/11	CI
Value Demonstration UK Holdings Limited reached an agreement to acquire Cello Health plc for approximately £170 million.	01/20/01	CI
Access Intelligence Plc commences an Equity Buyback Plan for 4,076,238 shares, for £0.000001 million, under the authorization approved on May 20, 2020.	04/20/04	CI
Tranche Update on Access Intelligence Plc's Equity Buyback Plan announced on June 4, 2020.	04/20/04	CI
Access Intelligence Plc's Equity Buyback announced on February 6, 2020, has closed with 4,076,238 shares, for £1 million.	04/20/04	CI
Cello Health plc Withdraws Recommendation to Pay Final Dividend	21/20/21	CI
Cello Health plc Withdraws Final Dividend; Declares Interim Dividend, Payable on May 22, 2020	07/20/07	CI
Cello Health plc Proposes Final Dividend, Payable on May 22, 2020	18/20/18	CI
Cello Health plc Reports Earnings Results for the Full Year Ended December 31, 2019	18/20/18	CI
Access Intelligence Plc acquired Fenix Media Limited and Face US Inc. from Cello Health plc and Cello Health Inc. for £4.7 million.	02/19/02	CI
Cello Health plc Announces Interim Dividend, Payable on November 1, 2019	18/19/18	CI
Cello Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	18/19/18	CI
Cello Health plc acquired trade and assets of Innovative Science Solutions, LLP for $10.5 million.	16/19/16	CI
Cello Health plc Provides Earnings Guidance for the Full Year 2019	18/19/18	CI
Cello Health Intends To Seek Acquisitions	18/19/18	CI
Cello Health plc Proposes Final Dividend, Payable on 24 May 2019	21/19/21	CI
Cello Health plc Reports Earnings Results for the Full Year Ended December 31, 2018	21/19/21	CI
Cello To Seek Acquisitions	21/19/21	CI
Cello To Seek Investments	21/19/21	CI
Cello Health plc Provides Earnings Guidance for the Year 2019	21/19/21	CI
Cello Health plc Announces Appointment of Michele Luzi as Non-Executive Director	12/18/12	CI
Cello Health plc Announces Executive Change	05/18/05	CI
Cello Health plc Appoints Julia Ralston as Executive Director	02/18/02	CI
Cello Group plc Declares an Interim Dividend; Payable on November 3, 2018	19/18/19	CI
Cello Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	19/18/19	CI

Chart Cello Health plc

Duration

Period

More charts

Company Profile

Cello Health plc, formerly Cello Group plc, is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company provides a range of biotech, diagnostics, devices and other non-healthcare clients. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company's pharmaceutical and healthcare clients. The Cello Signal Division provides market research and direct communications services to the Company's consumer facing clients. The Company delivers its services from office networks in the United Kingdom, the United States and Singapore.

Sector

More about the company